세포 치료 제조 시장 - 세계 산업 규모, 점유율, 동향, 경쟁, 기회, 예측 : 치료법별, 세포원별, 조업 규모별, 공급원별, 용도별, 최종사용자별, 지역별 및 경쟁 상황(2021-2031년)

The Global Cell Therapy Manufacturing Market is projected to expand from USD 5.71 Billion in 2025 to USD 11.42 Billion by 2031, reflecting a compound annual growth rate of 12.25%. This sector comprises specialized bioprocessing activities essential for isolating, genetically modifying, expanding, and cryopreserving viable cells used in autologous or allogeneic therapies. Market growth is primarily propelled by the increasing global prevalence of oncological and rare genetic disorders, creating an urgent need for curative interventions, while maturing regulatory environments encourage expedited approvals and investment in dedicated production infrastructure.

Data from the American Society of Gene & Cell Therapy and Citeline indicates that the global pipeline remained strong in 2025, with over 3,200 active trials. While this high volume of clinical candidates drives the need for extensive manufacturing capacity, the industry faces substantial hurdles related to cost-efficiency. Specifically, the complexity involved in preserving supply chain integrity from patient to patient, combined with the difficulties of scaling production, creates a significant barrier to lowering the high cost of goods sold for these advanced medical treatments.

Market Driver

Supportive regulatory environments and accelerated approval pathways are fundamentally transforming the manufacturing sector by speeding up the commercial launch of complex therapies. As health authorities optimize review procedures, the industry is rapidly moving from clinical-scale operations to high-volume commercial production, a shift underscored by a growing number of market participants. According to the Alliance for Regenerative Medicine, the sector achieved nine new product approvals in 2024 as of January 2025; this surge in authorizations demands resilient supply chains and scalable infrastructure capable of meeting strict quality standards under expedited timelines.

Consequently, there is an increasing dependence on Contract Development and Manufacturing Organizations as developers aim to avoid the heavy capital costs and technical burdens of building internal facilities. CDMOs are aggressively expanding to meet this outsourcing demand, as seen in Samsung Biologics' December 2025 announcement of a $4.8 billion investment for a new bio-campus featuring next-generation cell and gene therapy capabilities. This trend is further evidenced by Oxford Biomedica, which reported signing £149 million in new client orders during the first half of the year in September 2025, underscoring the critical role of specialized partners.

Market Challenge

The primary obstacles restricting the Global Cell Therapy Manufacturing Market's growth are the significant lack of cost-efficiency and the difficulties associated with maintaining supply chain integrity. High costs of goods sold, resulting from labor-intensive and unscalable workflows, inflate therapy prices to levels that challenge healthcare reimbursement systems. This economic pressure restricts the accessible patient demographic and deters the commercialization of treatments for broader conditions, effectively confining the market to niche indications where high costs are absorbed by payers.

According to the Alliance for Regenerative Medicine, 75% of the sector's global revenue in 2025 came from fewer than ten commercial products. This intense revenue concentration reveals a disconnect between a strong clinical pipeline and actual commercial viability, indicating a major bottleneck in converting clinical successes into profitable, scalable manufacturing operations. As a result, market expansion is hindered by the inability to support a diverse array of therapies, as the financial risks involved in scaling production remain prohibitively high for many developers.

Market Trends

The implementation of automated and closed-system processing platforms is becoming a vital solution to the industry's labor-intensive bottlenecks and consistency issues. Manufacturers are increasingly utilizing integrated smart factory modules that substitute manual handling with robotic precision, ensuring batch uniformity and reducing contamination risks. This technological evolution enables massive throughput scaling without requiring proportional increases in facility size or staff, as demonstrated by Cellares in September 2024, when it commissioned a New Jersey facility capable of producing up to 40,000 standard CAR-T cell therapy doses annually.

Simultaneously, the rise of decentralized and point-of-care production models is disrupting traditional centralized supply chains by placing manufacturing capabilities within or near clinical environments. This strategy drastically cuts vein-to-vein timelines and logistical hurdles by processing patient material on-site, effectively turning hospitals into biomanufacturing centers. Major academic and clinical institutions are funding this shift, as illustrated by The University of Texas MD Anderson Cancer Center's November 2024 launch of a new institute, backed by over $80 million, to accelerate the internal discovery and manufacturing of cell therapies.

Key Market Players

• Lonza
• Thermo Fisher
• Catalent
• WuXi AppTec
• Novartis
• Gilead
• Bristol Myers Squibb
• Merck KGaA
• Cytiva
• Charles River

Report Scope

In this report, the Global Cell Therapy Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Manufacturing Market, By Therapy

• T-Cell Therapies
• Dendritic Cell Therapies
• Tumor Cell Therapies
• Stem Cell Therapies

Cell Therapy Manufacturing Market, By Source of Cell

• Autologous v/s Allogenic

Cell Therapy Manufacturing Market, By Scale of Operation

• Preclinical
• Clinical
• Commercial

Cell Therapy Manufacturing Market, By Source

• In-House v/s Contract Manufacturing

Cell Therapy Manufacturing Market, By Application

• Oncology
• Cardiovascular Diseases
• Orthopedic Diseases
• Others

Cell Therapy Manufacturing Market, By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Cell Therapy Manufacturing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Manufacturing Market.

Available Customizations:

Global Cell Therapy Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Therapy Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
  • 5.2.2. By Source of Cell (Autologous v/s Allogenic)
  • 5.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
  • 5.2.4. By Source (In-House v/s Contract Manufacturing)
  • 5.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
  • 5.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Cell Therapy Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Source of Cell
  • 6.2.3. By Scale of Operation
  • 6.2.4. By Source
  • 6.2.5. By Application
  • 6.2.6. By End User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Therapy Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Source of Cell
      • 6.3.1.2.3. By Scale of Operation
      • 6.3.1.2.4. By Source
      • 6.3.1.2.5. By Application
      • 6.3.1.2.6. By End User
  • 6.3.2. Canada Cell Therapy Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Source of Cell
      • 6.3.2.2.3. By Scale of Operation
      • 6.3.2.2.4. By Source
      • 6.3.2.2.5. By Application
      • 6.3.2.2.6. By End User
  • 6.3.3. Mexico Cell Therapy Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Source of Cell
      • 6.3.3.2.3. By Scale of Operation
      • 6.3.3.2.4. By Source
      • 6.3.3.2.5. By Application
      • 6.3.3.2.6. By End User

7. Europe Cell Therapy Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Source of Cell
  • 7.2.3. By Scale of Operation
  • 7.2.4. By Source
  • 7.2.5. By Application
  • 7.2.6. By End User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Therapy Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Source of Cell
      • 7.3.1.2.3. By Scale of Operation
      • 7.3.1.2.4. By Source
      • 7.3.1.2.5. By Application
      • 7.3.1.2.6. By End User
  • 7.3.2. France Cell Therapy Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Source of Cell
      • 7.3.2.2.3. By Scale of Operation
      • 7.3.2.2.4. By Source
      • 7.3.2.2.5. By Application
      • 7.3.2.2.6. By End User
  • 7.3.3. United Kingdom Cell Therapy Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Source of Cell
      • 7.3.3.2.3. By Scale of Operation
      • 7.3.3.2.4. By Source
      • 7.3.3.2.5. By Application
      • 7.3.3.2.6. By End User
  • 7.3.4. Italy Cell Therapy Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Source of Cell
      • 7.3.4.2.3. By Scale of Operation
      • 7.3.4.2.4. By Source
      • 7.3.4.2.5. By Application
      • 7.3.4.2.6. By End User
  • 7.3.5. Spain Cell Therapy Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Source of Cell
      • 7.3.5.2.3. By Scale of Operation
      • 7.3.5.2.4. By Source
      • 7.3.5.2.5. By Application
      • 7.3.5.2.6. By End User

8. Asia Pacific Cell Therapy Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Source of Cell
  • 8.2.3. By Scale of Operation
  • 8.2.4. By Source
  • 8.2.5. By Application
  • 8.2.6. By End User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Therapy Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Source of Cell
      • 8.3.1.2.3. By Scale of Operation
      • 8.3.1.2.4. By Source
      • 8.3.1.2.5. By Application
      • 8.3.1.2.6. By End User
  • 8.3.2. India Cell Therapy Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Source of Cell
      • 8.3.2.2.3. By Scale of Operation
      • 8.3.2.2.4. By Source
      • 8.3.2.2.5. By Application
      • 8.3.2.2.6. By End User
  • 8.3.3. Japan Cell Therapy Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Source of Cell
      • 8.3.3.2.3. By Scale of Operation
      • 8.3.3.2.4. By Source
      • 8.3.3.2.5. By Application
      • 8.3.3.2.6. By End User
  • 8.3.4. South Korea Cell Therapy Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Source of Cell
      • 8.3.4.2.3. By Scale of Operation
      • 8.3.4.2.4. By Source
      • 8.3.4.2.5. By Application
      • 8.3.4.2.6. By End User
  • 8.3.5. Australia Cell Therapy Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Source of Cell
      • 8.3.5.2.3. By Scale of Operation
      • 8.3.5.2.4. By Source
      • 8.3.5.2.5. By Application
      • 8.3.5.2.6. By End User

9. Middle East & Africa Cell Therapy Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Source of Cell
  • 9.2.3. By Scale of Operation
  • 9.2.4. By Source
  • 9.2.5. By Application
  • 9.2.6. By End User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Therapy Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Source of Cell
      • 9.3.1.2.3. By Scale of Operation
      • 9.3.1.2.4. By Source
      • 9.3.1.2.5. By Application
      • 9.3.1.2.6. By End User
  • 9.3.2. UAE Cell Therapy Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Source of Cell
      • 9.3.2.2.3. By Scale of Operation
      • 9.3.2.2.4. By Source
      • 9.3.2.2.5. By Application
      • 9.3.2.2.6. By End User
  • 9.3.3. South Africa Cell Therapy Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Source of Cell
      • 9.3.3.2.3. By Scale of Operation
      • 9.3.3.2.4. By Source
      • 9.3.3.2.5. By Application
      • 9.3.3.2.6. By End User

10. South America Cell Therapy Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Source of Cell
  • 10.2.3. By Scale of Operation
  • 10.2.4. By Source
  • 10.2.5. By Application
  • 10.2.6. By End User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Therapy Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Source of Cell
      • 10.3.1.2.3. By Scale of Operation
      • 10.3.1.2.4. By Source
      • 10.3.1.2.5. By Application
      • 10.3.1.2.6. By End User
  • 10.3.2. Colombia Cell Therapy Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Source of Cell
      • 10.3.2.2.3. By Scale of Operation
      • 10.3.2.2.4. By Source
      • 10.3.2.2.5. By Application
      • 10.3.2.2.6. By End User
  • 10.3.3. Argentina Cell Therapy Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Source of Cell
      • 10.3.3.2.3. By Scale of Operation
      • 10.3.3.2.4. By Source
      • 10.3.3.2.5. By Application
      • 10.3.3.2.6. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Therapy Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lonza
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher
• 15.3. Catalent
• 15.4. WuXi AppTec
• 15.5. Novartis
• 15.6. Gilead
• 15.7. Bristol Myers Squibb
• 15.8. Merck KGaA
• 15.9. Cytiva
• 15.10. Charles River

16. Strategic Recommendations

17. About Us & Disclaimer